文献速递肝病

常规无创评分预测普通人群严重肝硬化相关疾病的前瞻性头对头比较

Prospective head-to-head comparison of routine non-invasive scores for predicting severe cirrhosis-related morbidity in the general population.
PubMed 文献 · Hepatology · 2026-03-23

本研究先在UK Biobank中系统比较了12种基于常规血液检测的纤维化评分与结局驱动评分对严重肝硬化相关疾病(ICD-10定义)的预测能力,共纳入385,738人,10年累积发病率为0.39%(1498例事件)。多数新评分优于APRI和FIB-4;LiverRisk的5年和10年C-index最高(0.847和0.812),CORE次之(0.839和0.811),但CORE的AUPRC更高(0.088 vs 0.063)。在转诊资源有限时,提高CORE阈值单用策略的净获益优于序贯CORE-LiverRisk策略。

要点

  • 在社区人群中,LiverRisk和CORE对10年严重肝硬化相关疾病的区分能力优于APRI和FIB-4。
  • CORE在高风险人群富集方面表现更好,AUPRC为0.088,高于LiverRisk的0.063。
  • 转诊比例低时,提高CORE阈值单用策略的净获益优于序贯CORE-LiverRisk策略。

核心结论

  • CORE和LiverRisk是预测社区长期严重肝硬化相关疾病最具区分度的常规血液无创工具。
  • 当转诊资源有限时,提高CORE阈值单用策略可能优于序贯CORE-LiverRisk策略。

研究设计与样本

  • 前瞻性头对头比较研究,先系统综述识别基于常规肝脏血液检测的风险评分,再在UK Biobank社区队列中评估。
  • 共纳入385,738名参与者,严重肝硬化相关疾病采用ICD-10编码定义。

主要发现

  • 系统综述识别出12个合格风险评分(10个新模型加APRI和FIB-4)。
  • 10年严重肝硬化相关疾病累积发病率为0.39%(1498例事件)。
  • 多数新评分优于APRI和FIB-4。
  • LiverRisk的5年C-index为0.847、10年C-index为0.812,区分度最高;CORE的5年C-index为0.839、10年C-index为0.811。
  • CORE的AUPRC为0.088,高于LiverRisk的0.063,高风险人群富集更好。

关键数值与推荐

  • LiverRisk 5年C-index 0.847、10年C-index 0.812。
  • CORE 5年C-index 0.839、10年C-index 0.811。
  • CORE AUPRC 0.088,LiverRisk AUPRC 0.063。
  • 在低转诊比例下,提高CORE阈值单用策略的净获益大于序贯CORE-LiverRisk策略。

临床怎么用

  • 在社区人群中可优先考虑CORE或LiverRisk进行肝硬化相关疾病风险分层。
  • 转诊资源有限时,可考虑提高CORE阈值单用策略以优化净获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Effective non-invasive risk-stratification tools are essential for the early detection of individuals at high risk for cirrhosis, to enable timely intervention. We conducted a prospective, head-to-head comparison of fibrosis-based and outcome-driven routine blood-based risk scores for predicting cirrhosis-related morbidity in a large community-based cohort. APPROACH AND RESULTS: We first performed a systematic review to identify risk scores derived from routine liver blood tests, and then evaluated them in the UK Biobank. Severe cirrhosis-related morbidity was defined using International Classification of Diseases, Tenth Revision codes. Discrimination and clinical utility were assessed using the Wolbers C-index, time-dependent area under the receiver operating characteristic curve, area under the precision-recall curve (AUPRC), and cumulative incidence accounting for competing risks. The review identified 12 eligible risk scores (10 novel models plus APRI and FIB-4). Among 385,738 participants, the 10-year cumulative incidence of severe cirrhosis-related morbidity was 0.39% (1498 events). Most novel scores outperformed APRI and FIB-4. LiverRisk showed the highest discrimination at 5 years (C-index 0.847) and 10 years (C-index 0.812), closely followed by CORE (5-year C-index 0.839; 10-year C-index 0.811). In contrast, CORE achieved better enrichment of high-risk individuals, with an AUPRC of 0.088 compared with 0.063 for LiverRisk. At low referral proportions, increasing the CORE threshold yielded greater net benefit than a sequential CORE-LiverRisk referral strategy. CONCLUSIONS: CORE and LiverRisk are the most discriminative routine blood-based tools for predicting long-term cirrhosis-related morbidity in the community. When referrals are limited, a higher-threshold CORE-only strategy may outperform a sequential CORE-LiverRisk approach.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Liang Z, Jin H, Gao W, et al. Prospective head-to-head comparison of routine non-invasive scores for predicting severe cirrhosis-related morbidity in the general population. Hepatology. 2026. PMID: 41875306. doi:10.1097/HEP.0000000000001749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。